MarginsXMarginsX
Home › Markets › Health Care › RCUS

Arcus Biosciences Inc. (RCUS)

RCUS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$16.86
-3.27% on the day
Market cap
$2.4B
Mid cap
Revenue · 2025
$247.0M
-4.3% on 2024
Net income · 2025
-$353.0M
-142.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1724521/000172452126000009/0001724521-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRCUS on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001724521
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$247.0M
Net income-$353.0M
Operating income-$386.0M
Net margin-142.9%
Operating margin-156.3%
Revenue growth-4.3%
Cash$222.0M
Total assets$1.1B
P/E (computed)Net income was not positive
P/S (computed)9.8×

Warning signs

Cash runway
3.9 months
$151.0M cash at September 30, 2026
Share count, 1 year
+33.4%
2025-10-23 to 2026-10-29 · +92.4% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$13.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$151.0M cash; operating cash flow -$116.3M a quarter.Report 2026-09-30
Shares outstanding143,990,614 (2026-10-29); 107,973,536 a year earlier; 74,855,565 three years earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedownsLatest 2026-10-22
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-03-11
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $13.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$9.0M-$128.0M-$88.0M$151.0M$102.0M$100.0M10-Q 2026-11-04
Q2 2026
2026-06-30
$41.0M-$91.0M-$119.0M$150.0M$101.0M$117.0M10-Q 2026-08-05
Q1 2026
2026-03-31
$17.0M-$128.0M-$138.0M$201.0M$100.0M$236.0M10-Q 2026-05-05
Q4 2025
2025-12-31
$33.0M-$106.0M-$120.0M$222.0M$99.0M$247.0M10-K 2026-02-25
Q3 2025
2025-09-30
$26.0M-$135.0M-$97.0M$238.0M$98.0M$240.0M10-Q 2026-11-04
Q2 2025
2025-06-30
$160.0M$0-$133.0M$248.0M$97.0M$262.0M10-Q 2026-08-05
Q1 2025
2025-03-31
$28.0M-$112.0M-$132.0M$192.0M$48.0M$141.0M10-Q 2026-05-05
Q4 2024
2024-12-31
$26.0M-$94.0M-$100.0M$150.0M$48.0M$258.0M10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-10-22
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 609 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.6%
1 month-22.6%
3 months-39.6%
Year to date-26.9%
1 year-11.9%
From 52-week high-44.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NAMSNewAmsterdam Pharma Company N.V.$19.46-3.38%$2.3B
HCMHUTCHMED (China) Limited$14.73-1.14%$2.6B
LKFTLakefront Biotherapeutics$34.79+2.38%$2.3B
PBHPrestige Consumer Healthcare Inc.$48.00+3.92%$2.3B
PHVSPharvaris N.V.$32.44-2.76%$2.3B
PRGOPerrigo Company plc$16.18-0.37%$2.2B
MBXMBX Biosciences Inc.$53.12-5.04%$2.6B
ZLABZai Lab Limited$23.47-4.59%$2.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier